Praxis Precision Medicines, Inc. (PRAX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 3M 6M 9M Q4 '22: 0 Q1 '23: 683K Q2 '23: 1.5M Q3 '23: 1.9M Q4 '23: 2.4M Q1 '24: 2.2M Q2 '24: 1.8M Q3 '24: 1.6M Q4 '24: 8.6M Q1 '25: 8.1M Q2 '25: 7.8M Q3 '25: 7.5M Q4 '25: 0 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '20: -38.2M Q3 '20: -43.8M Q4 '20: -62M Q1 '21: -80.9M Q2 '21: -105.8M Q3 '21: -134.4M Q4 '21: -167.3M Q1 '22: -208.8M Q2 '22: -232.7M Q3 '22: -232.2M Q4 '22: -215M Q1 '23: -184.2M Q2 '23: -158.8M Q3 '23: -140M Q4 '23: -126.4M Q1 '24: -130.2M Q2 '24: -132.7M Q3 '24: -164M Q4 '24: -200.2M Q1 '25: -233M Q2 '25: -271.6M Q3 '25: -293.1M Q4 '25: -326.2M Q1 '26: -357.3M Q2 '26: -378.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '20: -37.9M Q3 '20: -43.5M Q4 '20: -61.8M Q1 '21: -80.9M Q2 '21: -105.7M Q3 '21: -134.2M Q4 '21: -167.1M Q1 '22: -208.4M Q2 '22: -232.2M Q3 '22: -231.4M Q4 '22: -214M Q1 '23: -182.8M Q2 '23: -156.9M Q3 '23: -137.6M Q4 '23: -123.3M Q1 '24: -125.4M Q2 '24: -123.7M Q3 '24: -151M Q4 '24: -182.8M Q1 '25: -212.6M Q2 '25: -251M Q3 '25: -273M Q4 '25: -303.3M Q1 '26: -326.5M Q2 '26: -339.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '20: -42.3M Q4 '20: -52.6M Q1 '21: -69.8M Q2 '21: -89.8M Q3 '21: -99.9M Q4 '21: -124.6M Q1 '22: -152.9M Q2 '22: -180.1M Q3 '22: -201.1M Q4 '22: -185M Q1 '23: -163.8M Q2 '23: -137.8M Q3 '23: -116.1M Q4 '23: -111.1M Q1 '24: -99.1M Q2 '24: -95.2M Q3 '24: -99.5M Q4 '24: -131.8M Q1 '25: -163.9M Q2 '25: -191.3M Q3 '25: -228.9M Q4 '25: -249.1M Q1 '26: -282.2M Q2 '26: -305.1M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '20: -42.3M Q4 '20: -52.6M Q1 '21: -69.8M Q2 '21: -89.9M Q3 '21: -100.4M Q4 '21: -125.6M Q1 '22: -154.3M Q2 '22: -181.5M Q3 '22: -202.1M Q4 '22: -185.5M Q1 '23: -163.9M Q2 '23: -137.8M Q3 '23: -116.1M Q4 '23: -111.2M Q2 '25: -191.4M Q3 '25: -228.9M Q4 '25: -249.1M Q1 '26: -282.3M Q2 '26: -305.4M Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 1.6M Q3 '20: 1.7M Q1 '21: 38.5M Q2 '21: 41.6M Q3 '21: 44.7M Q1 '22: 45.5M Q2 '22: 45.5M Q3 '22: 45.8M Q1 '23: 3.5M Q2 '23: 4.6M Q3 '23: 9M Q1 '24: 13.9M Q2 '24: 18.8M Q3 '24: 18.9M Q1 '25: 21.1M Q2 '25: 21.5M Q3 '25: 22M Q1 '26: 28.9M Q2 '26: 29.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-90.00 -60.00 -30.00 0.00 30.00 60.00 90.00 Q2 '20: -27.55 Q3 '20: -32.04 Q4 '20: -7.86 Q1 '21: -2.49 Q2 '21: 4.91 Q3 '21: 16.01 Q4 '21: -3.92 Q1 '22: -4.72 Q2 '22: -5.16 Q3 '22: -5.12 Q4 '22: -69.65 Q1 '23: -78.72 Q2 '23: -84.78 Q3 '23: -86.54 Q4 '23: -22.64 Q1 '24: -14.90 Q2 '24: -9.26 Q3 '24: -9.29 Q4 '24: -10.33 Q1 '25: -10.78 Q2 '25: -12.35 Q3 '25: -12.96 Q4 '25: -13.47 Q1 '26: -13.38 Q2 '26: -12.94 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.